The development of protein farnesyltransferase and other ras-directed therapeutics for malignant diseases

Expert Opinion on Emerging Drugs

Volumn 5, Issue 2, 2000, Pages 161-199

  Rowinsky, Eric K ^a   Patnaik, Amita ^a  

^a CTRC Institute for Drug Development   (United States)

Author keywords

cancer; farnesylation; geranylgeranylation; protein farnesyltransferase; Ras antisense; ras oncogenes; Ras protein; signal transduction.

Indexed keywords

4 (8 CHLORO 5,6 DIHYDRO 11H BENZO[5,6]CYCLOHEPTA[1,2 B]PYRIDIN 11 YLIDENE) 1 (4 PYRIDYLACETYL)PIPERIDINE; ANTISENSE OLIGONUCLEOTIDE; CYTOKINE; CYTOTOXIC AGENT; GROWTH FACTOR; LONAFARNIB; NATURAL PRODUCT; PD 15440; PD 161956; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; SCH 66366; TIPIFARNIB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL CYCLE; CELL GROWTH; CELL MEMBRANE; CELL PROLIFERATION; CLINICAL TRIAL; COLON ADENOCARCINOMA; DRUG DESIGN; ENZYME ACTIVATION; ENZYME INHIBITION; GENE MUTATION; HUMAN; MALIGNANT TRANSFORMATION; METHODOLOGY; NONHUMAN; ONCOGENE RAS; PANCREAS ADENOCARCINOMA; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; REVIEW; TUMOR XENOGRAFT;

EID: 0033922954     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.5.2.161     Document Type: Review

References (221)

1. BOS JL: ras oncogenes in human cancer. A review. Cancer Res. (1989) 49:4682-4689. (Pubitemid 19213607)
2. BOLLAG G, MCCORMICK F: Regulators and effectors of ras proteins. Ann. Rev. Cell. Biol. (1991) 7:601-632.
3. BOGUSKI MS, MCCORMICK F: Proteins regulating Ras and its relatives. Nature (1993) 366:643-654. (Pubitemid 24036012)
4. LOWY DR, WILLUMSEN BM: Function and regulation of Ras. Ann. Rev. Biochem. (1993) 62:851-891. (Pubitemid 23237890)
5. LEONARD DM: Ras farnesyltransferase: a new therapeutic target. J. Med. Chem. (1997) 40:2971-2990. (Pubitemid 27391526)
6. SHIMIZU K, GOLDFARB M, SUARD Y et al.: Three human transforming genes are related to the viral oncogenes. Proc. Natl. Acad. Sci. USA (1983) 80:2112-2116. (Pubitemid 13097145)
7. GIBBS JB: Lipid modifications of proteins in the Ras superfamily. In: GTPases in Biology. Birnbaumer L, Dickey B (Eds.), Springer-Verlag, New York, NY, USA (1993):335-344.
8. HANCOCK JF, MAGEE AI, CHILDS JE, MARSHALL CJ: All ras proteins are polyisoprenylated but only some are palmitoylated. Cell (1989) 57:1167-1177. (Pubitemid 19169813)
9. HANCOCK JF, PATERSON H, MARSHALL CJ: A polybasic domain or palmitoylation is required for the addition of the CAAX motif to localize p21 to the plasma membrane. Cell (1990) 63:133-139.
10. JACKSON JH, COCHRANE CG, BOURNE JR et al.: Farnesyl modification of Kirsten-ras exon 4B protein is essential for transformation. Proc. Natl. Acad Sci. USA (1990) 87:3042-3046.
11. KATOK,COX AD, HISAKA MMet al.: Isoprenoidaddition to Ras protein is the critical modification for its membrane association and transforming activity. Proc. Natl. Acad. Sci. USA (1992) 89:6403-6407.
12. KHOSRAVI-FAR R, DER CJ: The Ras signal transduction pathway. Cancer Metastasis Rev. (1994) 13:67-89. (Pubitemid 24053340)
13. MCCORMICK F: Activators and effectors of ras p21 proteins. Curr. Opin. Genet. Dev. (1994) 4:71-76. (Pubitemid 24060298)
14. PAZIN MJ, WILLIAMS LT: Triggering signaling cascades by receptor tyrosine kinases. Trends Biochem. Sci. (1992) 17:374-378.
15. MCCORMICK F: How receptors turn Ras on. Nature (1993) 363:15-17.
16. CLARK GJ, DER CJ: Ras proto-oncogene activation in human malignancy. In: Cellular Cancer. Markers CT, Sell S (Eds.), Humana Press,Totowa, NJ, USA (1995):17-52.
17. POLAKIS P, MCCORMICK F: Interactions between p21ras proteins and their GTPase activating proteins. Cancer Surv. (1992) 12:25-42.
18. KHOSRAVI-FAR R, CAMPBELL S, ROSSMAN KL, DER CJ: Increasing complexity of Ras signal transduction: involvement of Rho family members. Adv. Cancer Res. (1998) 72:57-107. (Pubitemid 27435553)
19. MCCORMICK F: Ras biology in atomic detail. Nature Struct. Biol. (1996) 3:653-655. (Pubitemid 26260050)
20. STOKOE D, MACDONALD SG, CADWALLDER K et al.: Activation of Raf as a result of recruitment to the plasma membrane. Science (1994) 264:1463-1467. (Pubitemid 24217138)
21. LEEVERS SJ, PATERSON HF, MARSHALL CJ: Requirement for RasinRaf activationisovercomebytargeting Raf to the plasma membrane. Nature (1994) 369:411-414. (Pubitemid 24184056)
22. PRITCHARD C, MCMAHON M: Raf revealed in life-or-death decisions. Nature Genet. (1997) 16:214-215. (Pubitemid 27280198)
23. MORRISON DK, CUTLER RE, JR.: The complexity ofRaf-1 regulation. Curr. Opin. Cell. Biol. (1997) 9:174-179.
24. MARSHALL CJ: Cell signaling. Raf gets it together. Nature (1996) 383:127-128. (Pubitemid 26303963)
25. STANTON VP, NICHOLS DW, LAUDANO AP, COOPER GM: Definition of the human raf amino-terminal regulatory region by deletion mutagenesis. Mol. Cell. Biol. (1989) 9:639-647. (Pubitemid 19038867)
26. BURGERING BMT, BOS JL: Regulation of Ras-mediated signaling: more than one way to skin a cat. Trends Biochem. Sci. (1995) 20:18-22.
27. KOLCH W, HEODECLER G, LLOYD P, RAPP UR: Raf-1 protein kinase is required for growth of induced NIH/3T3 cells. Nature (1991) 349:426-428. (Pubitemid 21926105)
28. SCHAAP D, VAN DER WAL J, HOWE LR, MARSHALL CJ, VAN BLITTERSWIIK WJ: A dominant-negative mutant of rafblocks mitogen-activated protein kinase activation by growth factors and oncogenic p21ras. J. Biol. Chem. (1993) 268:20232-20236. (Pubitemid 23278927)
29. BONNER TI, KERBY SB, SUTRAVE P, GUNNELL MA, MARK G, RAPP UR: Structure and biological activity of human homologs of the raf/mil oncogene. Mol. Cell. Biol. (1985) 5:1400-1407. (Pubitemid 15090874)
30. OLDHAM SM, CLARK GJ, GANGAROSA LM, COFFEY RJ, DER CJ: Activation of the Raf-1/MAP kinase cascade is not sufficient for Ras transformation of RIE-1 epithelial cells. Proc. Natl. Acad. Sci. USA (1996) 93:6924-6928. (Pubitemid 26243476)
31. PRENDERGAST GC, GIBBS JB: Pathways ofRas function: connections to the actin cytoskeleton. Adv. Cancer Res. (1993) 62:19-64.
32. COWLEY S, PATTERSON H, KEMP P, MARSHALL CJ: Activation of MAP kinase is necessary and sufficient for PC12 differentiation and for transformationofNIH 3T3 cells. Cell (1994) 77:841-852. (Pubitemid 24187682)
33. MANSOUR SJ, MATTEN WT, HERMANN ASet al.: Transformation of mammalian cells by constitutively active MAP kinase kinase. Science (1994) 265:966-970. (Pubitemid 24281496)
34. STANG S, BOTTORFF D, STORE JC: Interaction of activated Ras with Raf-1 alone may be sufficient for transformation of rat2 cells. Mol. Cell. Biol. (1997) 17:3047-3055. (Pubitemid 27215019)
35. KHOSRAVI-FAR R, SOLSKI PA, CLARK GJ, KINCH MS, DER CJ: Activation of Rac1, RhoA and mitogen-activated protein kinases is required for Ras transformation. Mol. Cell. Biol. (1995) 15:6443-6453.
36. JONESON T, WHITE MA, WIGLER MH et al.: Stimulation of membrane ruffling and MAP kinase activation by distinct effectors of Ras. Science (1996) 271:810-812. (Pubitemid 26060736)
37. RIDLEY AJ, PATERSON HF, JOHNSTON CL, DIEKKMANN D, HALL A: The small GTP-binding protein Rac regulates growth-factor induced membrane ruffling. Cell (1992) 70:401-410.
38. RIDLEY AJ, HALL A: The small GTP-binding protein Rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell (1992) 70:389-399.
39. LANGE-CARTER CA, PLEIMAN CM, GARDNER AM et al.: A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf. Science (1993) 260:315-319. (Pubitemid 23160137)
40. LANGE-CARTER CA, JOHNSON GL: Ras-dependent growth factor regulation of MEK kinase in PC12 cells. Science (1994) 265:1458-1461. (Pubitemid 24306801)
41. MINDEN A,LIN A, MCMAHON Metal.: Differential activa-tionofERKand JNK mitogen-activated protein kinases by Raf-1 and MEKK. Science (1994) 266:1719-1723.
42. YAN M, DAI T, DEAK JC et al.: Activation of stress-activated protein kinase by MEKKI phosphorylation of its activator SEK1. Nature (1994) 372:798-800.
43. LIN M, MCMAHON M, LANGE-CARTER C et al.: Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 an d MEKK. Science (1994) 266:1719-1723.
44. DERIJARD B, HIBI M, WU I-H et al.: A protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell (1994) 76:1025-1037. (Pubitemid 24106383)
45. JOHNSON R, SPIEGELMAN B, HANAHAN D et al.: Cellular transformation and malignancy induced by ras require c-jun. Mol. Cell. Biol. (1996) 16:4504-4511. (Pubitemid 26251252)
46. HUNTER T: Oncoprotein networks. Cell (1997) 88:333-346. (Pubitemid 27131375)
47. RODRIGUEZ-VICIANA P, WARNE PH, DHAND R et al.: Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature (1994) 370:527-532. (Pubitemid 24264918)
48. CARPENTER CL, CANTLEY LC: Phosphoinositide kinases. Curr. Opin. Cell. Biol. (1996) 8:153-158. (Pubitemid 26109087)
49. YAN J, ROY S, APOLLONI A et al.: Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase. J. Biol. Chem. (1998) 273:24052-24056. (Pubitemid 28435747)
50. RODRIGUEZ-VICIANA P, WARNE PH, VANHAESEBROECK B et al.: Activation of phosphoinositide 3 kinase by interaction with Ras and by point mutation. EMBO J. (1996) 15:2442-2452.
51. RODRIGUEZ-VICIANA P, WARNE PH, KHWAJA A et al.: Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell (1997) 89:457-467. (Pubitemid 27220890)
52. KEELY PJ, WESTWICK JK, WHITEHEAD IP et al.: Cdc42 and Rac 1 induce integrin-mediated cell motility and invasiveness through PI(3)K. Nature (1997) 390:632-636. (Pubitemid 28016201)
53. TRESINI M, MAWAL-DEWAN M, CRISTOFALO VJ et al.: A phosphatidylinositol 3-kinase inhibitor induces a senescent-like growth arrest in human diploid fibroblasts. Cancer Res. (1998) 58:1-4. (Pubitemid 28027706)
54. YAO R, COOPER GM: Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science (1995) 267:2003-2006.
55. KENNEDY SG, WAGNER AJ, CONZEN SD et al.: The PI 3-kinase/Akt signaling pathway delivers an anti-apoptitic signal. Genes Dev. (1997) 11:701-713. (Pubitemid 27157159)
56. KHWAJA A, RODRIGUEZ-VICIANA P, WENNSTROM S et al.: Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J. (1997) 16:2783-2793. (Pubitemid 27226215)
57. KAUFFMAN-ZEH A, RODRIGUEZ-VICIANA P, ULRICH E et al.: Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature (1997) 385:544-548. (Pubitemid 27074674)
58. FRANKE TF, KAPLAN DR, CANTLEY LC: P13K: downstream AKTion blocks apoptosis. Cell (1997) 88:435-437. (Pubitemid 27154408)
59. CHUNG K, GRAMMER TC, LEMON KP et al.: PDGF-and insulin-dependent pp70S6k activation mediated by phosphatidylinositol-3-OH kinase. Nature (1994) 370:71-75.
60. BANERJEE P, AHMAD MF, GROVE JR et al.: Molecular structure of a major insulin/mitogen-activated 70-kDa S6 protein kinase. Proc. Natl. Acad. Sci. USA (1990) 87:8550-8554.
61. CHUNG J, KUO CJ, CRABTREE GRet al.: Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell (1992) 69:1227-1236.
62. LANE HA, FERNANDEZ A, LAMB NJC et al.: p70s6k function is essential for G1 progression. Nature (1993) 363:170-172.
63. PERUCHO M, GOLDFARB M, SHIMIZU K et al.: Human tumor-derived cell lines contain common and different transforming genes. Cell (1981) 27:467-476.
64. CASEY PJ: p21 Rasismodified byafarnesyl isoprenoid. Proc. Natl. Acad. Sci. USA (1989) 86:8323-8327.
65. BEAUPRE DM, KURZROCK R: RAS and leukemia: from basic mechanisms to gene-directed therapy. J. Clin. Oncol. (1999) 17:1071-1079. (Pubitemid 29109341)
66. GELB MH: Protein prenylation, et cetera: signal transduction in two dimensions. Science (1997) 275:1750-1751. (Pubitemid 27136701)
67. COX AD, DER CJ: Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochem. Biophys. Acta. (1997) 1333:F51-F71. (Pubitemid 27359966)
68. OMER CA, ANTHONY NJ, BUSER-DOEPNER CA et al.: Farnesyl protein transferase inhibitors as agents to inhibit tumor growth. Biofactors (1997) 6:359-366. (Pubitemid 27487811)
69. GIBBS JB, OLIFF A: The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Ann. Rev. Pharmacol. Toxicol. (1997) 37:143-166. (Pubitemid 27238873)
70. YAMANE HK, FARNSWORTH CC, XIE HY et al.: Brain Gprotein gamma subunits contain all trans-geranylgeranlycysteine methyl ester at their carboxyl termini. Proc. Natl. Acad. Sci. USA (1990) 87:5868-5872.
71. SCHAFER WR, KIM R, STERNE R et al.: Genetic and pharmacological suppression of oncogenic mutations in ras genes of yeast and humans. Science (1989) 245:379-385. (Pubitemid 19203359)
72. HANCOCK JF, CADWALLADER K, MARSHALL CJ: A CAAX or a CAAL motif and a second signal are sufficient for plasma membrane targeting of ras proteins. EMBO J. (1991) 110:641-646.
73. DUDER T, GELB MH: Palmitoylation of H-Ras facilitates membrane binding, activation of downstream effectors and meiotic maturation in Xenopus oocytes. J. Biol. Chem. (1996) 271:11541-11547. (Pubitemid 26155999)
74. GHOMASHCHI F, ZHANG X, LIU L et al.: Binding of prenylated and polybasic peptides to membranes: affinities and intervesicle exchange. Biochemistry (1995) 34:11910-11918.
75. ZHANG FL, CASEY PJ: Protein prenylation: molecular mechanisms and functional consequences. Ann Rev. Biochem. (1996) 65:241-269. (Pubitemid 26250610)
76. REISS Y, GOLDSTEIN JL, SEABRA MC et al.: Inhibitors of purified p21rasfarnesyl: protein transferasebycys-AAX tetrapeptides. Cell (1990) 62:81-88.
77. REISS Y, STRADLEY SJ, GIERASCH LM et al.: Sequence requirement for peptide recognitionbyrat brain p21ras protein farnesyltransferase. Proc. Natl. Acad. Sci. USA (1991) 88:732-736. (Pubitemid 21916097)
78. PARK HW, BODULURI SR, MOOMAW JF et al.: Crystal structure of protein farnesyltransferase at 2.25 angstrom resolution. Science (1997) 275:1800-1804. (Pubitemid 27136719)
79. DUNTEN P, KAMMLOT U, CROWTHER R, WEBER D, PALMERO R, BIRKTOFT J: Protein farnesyltransferase: structure and implications for function. Biochemistry (1997) 37:7907-7912.
80. ANDRES DA, GOLDSTEIN JL, HO YK et al.: Mutational analysis of alpha-subunit of protein farnesyltransfe-rase: evidence for a catalytic role. J. Biol. Chem. (1993) 268:1383-1390. (Pubitemid 23019788)
81. KUMAR A, BERSINI MH, DHAWAN P et al.: Alpha-subunit of farnesyltransferase is phosphorylated in vivo: effect of protein phosphatase-1 on enzymatic activity. Biochem. Biophys. Res. Commun. (1996) 222:445-452. (Pubitemid 26335036)
82. VOGT A, SUN J, QIAN Y et al.: Burkitt lymphoma Daudi cells contain two distinct farnesyltransferases with different divalent cation requirements. Biochemistry (1995) 34:12398-12403.
83. YOKOYAMA K, ZIMMERMAN K, SCHOLTEN MH: Differential prenyl pyrophosphate binding to mammalian protein geranylgeranyltransferase-I and protein farnesyltransferase and its consequence on the specificity of protein prenylation. J. Biol. Chem. (1997) 272:3944-3952. (Pubitemid 27078452)
84. CLARKE S: Protein isoprenylation and methylation at carboxyl-terminal cysteine residues. Ann. Rev Biochem. (1992) 61:355-386.
85. CASEY PJ, SEABRA MC: Protein prenyltransferases. J. Biol. Chem. (1996) 271:5289-5292. (Pubitemid 26083855)
86. JAMES GL, GOLDSTEIN JL, BROWN MS: Polylysine and CVIMsequencesofKrasB dictate specificityofprenyla-tion and confer resistance to benzodiazepine peptidomimetics in vitro. J. Biol. Chem. (1995) 266:14603-14610.
87. ARMSTRONG SA, HANNAH VC, GOLDSTEIN JL et al.: CAAX geranylgeranyl transferase transfers.
88. COX AD, HISAKA MM, BUSS JE et al.: Specific isoprenoid modification is required for function of normal, but not oncogenic, Ras protein. Mol. Cell. Biol. (1992) 12:2606-2615.
89. GIBBS JB, OLIFF A, KOHL NE: Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell (1994) 77:177-178.
90. JAMES GL, GOLDSTEIN JL, PATHAK RK et al.: PxF, a prenylated proteinofperoxisomes. J. Biol. Chem. (1994) 269:14182-14190.
91. SYMONS M: The Rac and Rho pathways as a source of drug targets for Ras-mediated malignancies. Curr. Opin. Biotechnol. (1995) 6:668-774.
92. GOLDSTEIN JL, BROWN MS, STRADLEY SJ et al.: Nonfar-nesylated tetrapeptide inhibitors of protein farnesyl-transferase. J. Biol. Chem. (1991) 266:15575-15578. (Pubitemid 21907690)
93. SEBTI SM, HAMILTON AD: New approaches to anticancer drug design based on the inhibition of farnesyltransferase. Drug Discov. Today (1998) 3:26-33. (Pubitemid 28078839)
94. HEIMBROOK DC, OLIFF A: Therapeutic intervention and signaling. Curr. Opin. Cell. Biol. (1998) 10:284-288. (Pubitemid 28174772)
95. POMPLIANO DL, RANDS E, SCHABER MD, MOSSER SD, ANTHONY NJ, GIBBS JB: Steady-state kinetic mechanism of Ras farnesyl: protein transferase. Biochemistry (1992) 31:3800-3807.
96. BROWN MS, GOLDSTEIN JL, PARIS KJ et al.: Tetrapeptide inhibitors of protein farnesyltransferase: amino-terminal substitution in phenylalanine- containing tetrapeptides restores farnesylation. Proc. Natl. Acad. Sci. USA (1992) 89:8313-8316.
97. REISS Y, GOLDSTEIN JL, SEABRA MC, CASEY PJ, BROWN MS: Inhibition of purified p21 Ras farnesyl: protein transferase by Cys-AAX tetrapeptides. Cell (1990) 62:81-88.
98. KOHL NE, MOSSER SD, DESOLMS SJ: Selective inhibition of ras-dependent transformation by a farnesyltransfe-rase inhibitor. Science (1993) 260:1934-1937. (Pubitemid 23258273)
99. GRAHAM SL, SMITH RL, SCOLNICK EM, OLIFF A, GIBBS JB: Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science (1993) 260:1934-1937. (Pubitemid 23258273)
100. KOHL NE, WILSON FR, MOSSER SD et al.: Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc. Natl. Acad. Sci. USA (1994) 91:9141-9145.
101. SEPP-LORENZINO L, MA Z, RANDS E et al.: A peptidomi-metic inhibitor of farnesyl: protein transferase blocks the anchorage-dependent and-independent growth of human tumor cell lines. Cancer Res. (1995) 55:5302-5309.
102. DESOLMS SJ, DEANA AA, GIULIAN EA et al.: Pseudo-dipeptide inhibitors of protein farnesyltransferase. J. Med. Chem. (1995) 38: 3967-3971.
103. LERNER EC, QIAN Y HAMILTON AD et al.: Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor. J. Biol. Chem. (1995) 270:26770-26773.
104. VOGT A, QIAN Y, BLASKOVICH MA, FOSSUM RD, HAMILTON AD, SEBTI SM: A non-peptide mimetic of Ras-CAAX: selective inhibition of farnesyltransferase and Ras processing. J. Biol. Chem. (1995) 270:660-664.
105. QIAN Y, VOGT A, SEBTI SM, HAMILTON AD: Design and synthesisof non-peptide Ras CAAX mimeticsaspotent farnesyltransferase inhibitors. J. Med. Chem. (1996) 39:217-223. (Pubitemid 26023515)
106. NAGASU T, YOSHIMATSU K, ROWELL C et al.: Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res. (1995) 270:26770-26773.
107. JAMES GL, GOLDSTEIN JL, BROWN MS et al.: Benzodi-azepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. Science (1993) 260:1937-1942. (Pubitemid 23258274)
108. JAMES GL, BROWN MS, COBB MH, GOLDSTEIN JL: Benzodiazepine peptidomimetic BZA-5B interrupts the MAP kinase activation pathway in H-Ras-transformed Rat-1 cells, but not in untransformed cells. J. Biol. Chem. (1994) 269: 27705-27714. (Pubitemid 24346609)
109. MARSTERS JC, MCDOWELL RS, REYNOLDS ME et al.: Benzodiazepine peptidomimetic inhibitors of farnesyltransferase. Bioorg. Med. Chem. (1994) 2:949-957.
110. QIAN Y, BASKOVICH MA, SALEEM M et al.: Design and structural requirements of potent peptidomimetic inhibitors of p21 Ras farnesyltransferase. J. Biol. Chem. (1994) 269:12410-12413.
111. LEFTHERIS K, KLINE T, VITE GD et al.: Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity. J. Med. Chem. (1996) 39:353-358.
112. HUNT JT, LEE VG, LEFTHERIS K et al.: Potent cell active, non-thiol tetrapeptide inhibitors of farnesyltransfe-rase. J. Med. Chem. (1996) 39:353-358. (Pubitemid 26041449)
113. LEONARD D, SHULER KR, POULTER CJ et al.: Structure-activity relationships of cysteine-lacking pentapeptide derivatives that inhibit ras farnesyltransferase. J. Med. Chem. (1997) 40:192-200. (Pubitemid 27045075)
114. SCHOLTEN JD, ZIMMERMAN K, OXENDER Met al.: Inhibitors of farnesyl: protein transferase-a possible cancer chemotherapeutic. Bioorg. Med. Chem. (1996) 9:1537-1543. (Pubitemid 26320003)
115. LIU M, BRYANT MS, CHEN J et al.: Antitumor activity of SCH66336 and orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograftmodels and wap-ras transgenic mice.Cancer Res. (1998) 58:4947-4956. (Pubitemid 28503695)
116. MALLAMS AK, NOJOROGE FG, DOLL RJ et al.: Antitumor 8- chlorobenzocycloheptapyridines: a new class of selective, nonpeptidic, nonsulfhydryl inhibitors of ras farnesylation. Bioorg. Med. Chem. (1997) 5:93-99. (Pubitemid 27065353)
117. NJOROGE FG, DOLL RJ, VIBULBHAN Bet al.: Discovery of novel nonpeptidic tricyclic inhibitors of Ras farnesyl protein transferase. Bioorg. Med. Chem. (1997) 5:101-113. (Pubitemid 27065354)
118. BISHOP WR, BOND R, PETRIN J et al.: Novel tricyclic inhibitor of farnesyl protein transferase: biochemical characterization and inhibition of Ras modification in transfected Cos cells. J. Biol. Chem. (1995) 270:30611-30618.
119. STRICKLAND CL, WEBER PC, WINDSOR WT et al.: Tricyclic farnesyl protein transferase inhibitors: crystallographic and calorimetric studies of structure activity relationships. J. Med. Chem. (1999) 42:2125-2135. (Pubitemid 29284232)
120. VENET M, ANGIBAUD P, SANZ G et al.: Synthesis and in vitro structure-activity relationships of imidazolyl-2-quinolinones as farnesyl protein transferase inhibitors. Proc. Am. Assoc. Cancer Res. (1998) 39:2171.
121. TODD AV, APPLEGATE TL, FUERYU CJ et al.: Farnesyl transferase inhibitor (FTI): effect on ras activation. Proc. Am. Assoc. Cancer Res. (1998) 39:2168A.
122. END D, SKRZAT S, DEGVINE A et al.: R115777, a novel imidazole farnesyl protein transferase inhibitor (FTI): biochemical and cellular effects in H-ras and K-ras dominant systems. Proc. Am. Assoc. Cancer Res. (1998) 39:1847.
123. MANNE V, YAN N, CARBONI JM et al.: Bisubstrate inhibi tors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells. Oncogene (1995) 10:1763-1779.
124. PATEL DV, GORDON EM, SCHMIDT RJ et al.: Phosphinyl acid-based bisubstrate anlog inhibitors of Ras farnesyl protein transferase. J. Med. Chem. (1995) 38:435-442.
125. YAN N, RICCA C, FLETCHER J et al.: Farnesyltransferase inhibitors block the neurofibromatosis Type I (NF1) malignant phenotype. Cancer Res. (1995) 55:3569-3575.
126. BASU TN, GUTMANN DH, FLETCHER JA et al.: Aberrant regulation of ras proteins in malignant tumor cells from Type I neurofibromatosis patients. Nature (1992) 356:713-715.
127. DECLUE JE, PAPAGEORGE AG, FLETCHER JA et al.: Abnormal regulation of mammalian p23ras contrib-utestomalignant tumorgrowthinvonReckinghausen (Type 1) neurofibromatosis. Cell (1992) 69:256-273.
128. KAINUMA O, ASANO T, HASEGAWA M et al.: Inhibitor of growth and invasive activity of human pancreatic cancer cells by a farnesyltransferase inhibitor, manumycin. Pancreas (1997) 15:379-383. (Pubitemid 27525634)
129. HOHL RJ, LEWISK: Differentialeffectsofmonoterpenes and lovastatin on ras processing. J. Biol. Chem. (1995) 270:17508-17512.
130. SUN JA, ELSON CE, TANNER MA, GOULD MN: Inhibition of DMBA-induced mammary cancer by monoterpene d-limonene. Carcinogenesis (1984) 5:661-664. (Pubitemid 14108578)
131. ELSON CE, MALTZMAN TH, BOSTON JL, TANNER MA, GOULD MN: Anti-carcinogenic activity of d-limonene during the initiation and promotion/progression stagesofDMBA-induced rat mammary carcinogenesis. Carcinogenesis (1998) 331-332.
132. HAAG ID, LINDSTROM MJ, GOULD MN: Limonene-induced regression of mammary carcinoma. Cancer Res. (1992) 52:4021-4026.
133. CROWELL PL, RENZ, LIN S, VEDEJS E, GOULD MN: Structure activity relationships among monoterpene inhibitors of protein isoprenylation and cell proliferation. Biochem. Pharmacol. (1994) 47:1405-1415. (Pubitemid 24130935)
134. HOHL RJ: Monoterpenesasregulatorsofmalignant cell proliferation. Adv. Exp. Med. Biol. (1996) 401:137-46.
135. STAYBROOK KR, MCKINZIE JH, BARBHAIYA LH, CROWELL PL: Effects of the antitumor agent perillyl alcohol on H-ras vs. K-ras farnesylation and signal transduction. Anticancer Res. (1998) 18:823-828. (Pubitemid 28239601)
136. REN Z, ELSON CE, GOULD MN: Inhibition of Type I and Type II geranylgeranyl protein transferases by the monoterpene perillyl alcohol in NIH3T3 cells. Biochem. Pharmacol. (1997) 54:113-120. (Pubitemid 27353228)
137. REN Z, GOULD MN: Inhibition of ubiquinone and cholesterol synthesis by the monoterpene perillyl alcohol. Cancer Lett. (1994) 76:185-190. (Pubitemid 24068295)
138. GELB MH, TAMANOL F, KOHEL Y, GHOMASHCHI F, ESSON K, GOULD M: The inhibition of protein prenyl-transferases by oxygenated metabolites of limonene and perillyl alcohol. Cancer Lett. (1995) 91:169-175.
139. HARDCASTLE IR, ROWLANDS MG, BARBER AM et al.: Inhibition of protein prenylation by metabolites of limonene. Biochem. Pharmacol. (1999) 57:801-809. (Pubitemid 29094551)
140. AIAZI EA, SATOMI Y, ELLIS MJ et al.: Activation of the transforming growth factor P signaling pathway and induction of cytostasis and apoptosis in mammary carcinomas treated with the anticancer agent perillyl alcohol. Cancer Res. (1999) 59:1917-1928. (Pubitemid 29186166)
141. RIPPLE GH, GOULD MN, STEWART JA et al.: Phase I clinical trial of perillyl alcohol administered daily. Clin. Can. Res. (1998) 4:1159-1164. (Pubitemid 28213326)
142. SUN J, QIAN Y, HAMILTON AD et al.: Both farnesyltrans-ferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenyla-tion but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Oncogene (1998) 16:1467-1473. (Pubitemid 28151853)
143. MIGUEL K, PRADINES A, SUN J et al.: GGTI-228 induces G0-G1 block and apoptosis whereas FTI-227 causes B2-M enrichment in A549 cells. Cancer Res. (1997) 57:1846-1850. (Pubitemid 27209708)
144. VOGT A, SUN J, QIAN Y et al.: The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in B0/G1 and induces p1WAF/CIP/SDII in a p53-independent manner. J. Biol. Chem. (1997) 272:27224-27229. (Pubitemid 27452683)
145. CHANG EH, MILLER PS, CUSHMAN C et al.: Antisense inhibition of ras p21 expression that is sensitive to point mutation. Biochemistry (1991) 30:8283-8286.
146. MONIA BP, JOHNSTON JF, ECKER DJ et al.: Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. J. Biol. Chem. (1992) 267:19954-19962.
147. GRAY GD, HERNANDEZ OM, HEBEL D, ROOT M, POW-SANG JM, WICKSTROM E: Antisense DNA inhibi-tionof tumor growth inducedby c-Ha-ras oncogene in nude mice. Cancer Res. (1993) 53:577-580. (Pubitemid 23059439)
148. WICKSTROM E: Antisense tumor therapy: activated c-Ha-ras oncogene in the mouse. In: Methods in Molecular Medicine: Antisense Therapeutics. Agrawal S (Ed.), Humana Press, Totowa, NJ, USA (1996):87-108.
149. SCHWAB G, CHAVANY C, DUROUX I et al.: Antisense oligonucleotides absorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice. Proc. Natl. Acad. Sci. USA (1994) 91:10460-10464. (Pubitemid 24329017)
150. DORR A, BURCE J, MONIA B et al.: Phase I and pharma-cokinetic trial of ISIS 2503, a 20-mer antisense oligonu-cleotide against H-ras by 14-day continous infusion (CIV) in patients with advance cancer. Proc. Am. Soc. of Clin. Oncol. (1999) 18:603.
151. ADJEI A, ERLICHMAN C, SLOAN J et al.: A Phase I trial of Isis 2503, an antisense inhibitor of H-Ras in combination with gemcitabine in patients with advanced cancer. Proc. Am. Soc. of Clin. Oncol. (2000) 19:722.
152. MUKHOPADHYAY T, TAINSKY M, CAVENDAR AC, ROTH JA: Specific inhibition of K-ras expression and tumori-genicity of lung cancer cells by antisense RNA. Cancer Res. (1991) 51:1744-1748.
153. GEORGESR,MUKHOPADYAYT,ZHANGY,YENN,ROTH JA: Prevention of orthotopic human lung cancer growth by intrateracheal instillation of a retroviral antisense K-ras construct. Cancer Res. (1993) 53:1743-1746. (Pubitemid 23127096)
154. ALEMANY R, RUAN S, MASAFUMI K et al.: Growth inhibitory effect of anti-K-ras adenovirus on lung cancer cells. Cancer Gene Ther. (1996) 3:296301.
155. ROTH JA: Modification of mutant K-ras gene in nonsmall cell lung cancer (NSCLC). Hum. Gene Ther. (1996) 7:875-889. (Pubitemid 26146444)
156. AOKI K, YOSHIDA T, SUGIMURA T, TERADA M: Liposome mediated transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. Cancer Res. (1995) 55:3810-3816.
157. AOKI K, TOSHIDA T, MATSUMOTO N, IDE H, SUGIMURA T, TERADA M: Suppression of K-ras p21 levels leading to growth inhibition of pancreatic cancer cells lines with k-ras mutation but not those without Ki-ras mutation. Mol. Carcinog. (1997) 20:251-258. (Pubitemid 27508889)
158. O'DWYER PJ, STEVENSON JP, GALLAGHER M et al.: c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleo-tide ISIS 5132 (CGP 69846A). Clin. Cancer Res. (1999) 12:3977-3982. (Pubitemid 30013773)
159. STEVENSON JP, YAO KS, GALLAGHER M et al.: Phase I clinical/ pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A). J. Clin. Oncol. (1999) 17:2227-2236. (Pubitemid 29318857)
160. GARCIA AM, ROWELLC,ACKERMANN Ketal.: Peptidomi-metic inhibitors of Ras farnesylation and function in whole cells. Biol. Chem. (1993) 268:18415-18418. (Pubitemid 23273764)
161. PRENDERGAST GC, DAVIDE JP, DESOLMS SJ et al.: Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol. Cell Biol. (1994) 14:4193-4202.
162. FIORDALISI JJ, RUSHTON BC, TOURSSAINT LF III et al.: High affinity for FTase and alternative prenylation contribute individually to K-ras resistance to FTIs. Proc. Am. Assoc. Can. Res. (1999) 40:521.
163. JAMES G, GOLDSTEIN JL, BROWN MS: Resistance of K-RasBV12 proteins to farnesyltransferase inhibitors in Rat1 cells. Proc. Natl. Acad. Sci. USA (1996) 93:4454-4458.
164. JACKSON JH, LI JW, BUSS JE et al.: Polylysine domain of K-ras 4B protein is crucial for malignant transforma tion. Proc. Natl. Acad. Sci. USA (1994) 91:12730-12734.
165. LERNER EC, QIAN Y, BLASKOVICH MA et al.: Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras/Raf complexes. J. Biol. Chem. (1995) 270:26802-26806. (Pubitemid 3007240)
166. SUN J, QIAN Y, HAMILTON AD et al.: Ras CAAX peptidomimetic FTI-276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. Cancer Res. (1995) 55:4243-4247.
167. WHYTE DB, KIRSCHMEIER P, HOCKENBERRY TNet al.: K-and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem. (1997) 272:14459-14464. (Pubitemid 27232866)
168. ROWELL CA, KOWALCZYK JJ, LEWIS MD et al.: Direct demonstration of geranylgeranylation and farnesyla-tion of Ki-Ras in vivo. J. Biol. Chem. (1997) 272:14093-14097. (Pubitemid 27232813)
169. LEBOWITZ PF, DAVIDE JP, PRENDERGAST GC: Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity. Mol. Cell Biol. (1995) 15:6613-6622.
170. LEBOWITZ PF, SAKAMURO D, PRENDERGAST GC: Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment. Cancer Res. (1997) 57:708-713. (Pubitemid 27085655)
171. HUNG W-C, CHAUNG L-Y: The farnesyltransferase inhibitor FPT inhibitor III upregulates Bax and Bcl-xs expression and induces apoptosis in human ovarian cancer cells. Int. J. Oncol. (1998) 12:137-140. (Pubitemid 28027239)
172. SMETS G, VANEYCK N, DEVINE A et al.: R115777, a selective farnesyl protein transferase inhibitor, induces predominately apoptotic activity in C32 melanoma tumor xenografts. Proc. Am. Assoc. Cancer Res. (1999) 40:522.
173. DU W, PRENDERGAST GC: Activation of the PI3-AKT pathway masks the proapoptotic effects of farnesyl-transferase inhibitors. Cancer Res. (1999) 59:4208-4212. (Pubitemid 29418727)
174. GIBBS JP: Ras c-terminal processing enzymes: new drug targets? Cell (1991) 65:1-4.
175. MIYAKE M, MIZUTANI S, KOIDE H et al.: Unfarnesylated transforming Ras mutant inhibits the Ras-signaling pathway by forming a stable. Ras complex in the cytosol. FEBS Lett. (1992) 378:15-18.
176. PRENDERGAST GC, DAVIDE JP, LEBOWITZ PF et al.: Resistance of a variant Ras transformed cell line to phenotypic reversion by farnesyltransferase inhibitors. Cancer Res. (1996) 56:2626-2632. (Pubitemid 26170701)
177. SKRZAT S, ANGIBAUD P, VENET M et al.: R115777, a novel imidazole farnesyl protein transferase inhibitor (FTI) with potent oral antitumor activity. Proc. Am. Assoc. Cancer Res. (1998) 39:2169A.
178. SMETS G, XHONNEUX B, CORNELISSEN F et al.: R115777, a selective farnesyl protein transferase inhibitor (FTI), induces antiangiogenic, apoptotic and anti-proliferative activity in CAPAN-2 and LoVo tumor xenografts. Proc. Am. Assoc. Cancer Res. (1998) 39:2170A.
179. FELDKAMP M, LAU N, GUHA A: The farnesyl transferase inhibitor SCH66336 inhibits the growth of human astrocytoma cell lines and xenografts implanted in NOD-SCID mice. Proc. Am. Assoc. Cancer Res. (2000) 41:2834.
180. ROSE WC, ARICO MA, BURKE CL et al.: Preclinical antitumor activity of BMS-214662, a novel farnesyl transferase inhibitor. Proc. Am. Assoc. Cancer Res. (2000) 41:2835.
181. KOHL NE, OMER CA, CONNER MW et al.: Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomasinras transgenic mice. Nature Med. (1995) 1:792-797.
182. SINN E, MULLER W, PATTENGALE P et al.: Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice; Synergistic action of oncogenes in vivo. Cell (1987) 49:465-475. (Pubitemid 18091823)
183. HUNDLEY JE, KOESTER SK, TROYER DA et al.: Increased tumor proliferation and genomic instability without decreased apoptosis in MMTV-ras mice deficient in p53. Mol. Cell Biol. (1997) 17:723-731. (Pubitemid 27045746)
184. SHI B, YAREMKOB, HAJIAN Get al.: The farnesyl protein transferase inhibitor SCH66336 synergizes with the taxanes in vitroand enhances their anti-tumor activity in vivo. Cancer Chemother. Pharmacol. (2000) (In Press).
185. NIELSEN LL, SHI B, HAJIAN G et al.: Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH5850 (p53 adenovirus) in preclinical cancer models. Cancer Res. (1999) 59:5896-5901. (Pubitemid 30004947)
186. YONISH-ROUACH E: The p53 tumour suppressor gene: a mediator of a G1 growth arrest and of apoptosis. Experientia (1996) 52:1001-1007. (Pubitemid 26379182)
187. BARRINGTON RE, SUBLER MA, RANDS Eet al.: A farnesyl-transferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol. Cell. Biol. (1998) 18:85-92. (Pubitemid 28021020)
188. DONEHOWER LA, HARVEY M, SLAGLE BL et al.: Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature (1992) 356:215-221.
189. ADJEI AA, ERLICHMAN C, DAVIS J et al.: A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res. (2000) 60:1871-1877. (Pubitemid 30207646)
190. ADJEI AA, DAVIS JN, ERLICHMAN C et al.: Comparison of potential surrogate markers of farnesyltransferase inhibition. Clin. Cancer Res. (2000) 6:2318-2325. (Pubitemid 30399198)
191. BECK LA, HOSICK TJ, SINENSKY M: Isoprenylation is requiredfor the processingofthe laminAprecursor. J. Cell Biol. (1990) 110:1489-1499.
192. SOIGNET S, YAO S-L, BRITTEN D et al.: Pharmacoki-netics and pharmacodynamics of the farnesyl protein transferase inhibitor (L-778,123) in solid tumors. Proc. Am. Assoc. Can. Res. (1998) 40:517.
193. KILIC F, DALTON MB, BURRELL SK et al.: In vitro assay and characterization of the farnesyl-dependent prelamin A. Cancer Res. (1994) 54:3229-3232.
194. SINENSKY M, FANTLE K, DALTON M: An antibody which specifically recognizes prelamin A but not mature lamin A: application to detection of blocks in farnesylation-dependent protein processing. Cancer Res. (1994) 54:3229-3232. (Pubitemid 24208933)
195. MINAMI Y, MINAMI M: Hsc70/Hsp40 chaperone system mediates the Hsp90-dependent refolding of firefly luciferase. Genes Cells (1999) 4:721-729. (Pubitemid 30053319)
196. SINENSKY M, LUTZ RJ: The prenylation of proteins. Bioessays (1992) 14:25-31.
197. HANCOCK JF: Prenylation and palmitoylation analysis. Methods Enzymol. (1995) 25:237-245.
198. JOHNSTON SR, ELLIS PA, HOUSTON S et al.: A phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced breast cancer. Proc. Am. Soc. Clin. Oncol. (2000) 19:318.
199. ZUJEWSKI J, HORAK ID, BOL CJ et al.: A Phase I study of farnesyl protein transferase inhibitor, R115777, in advanced cancer. J. Clin. Oncol. (2000) 18:927-934.
200. HUDES G, SCHOL J, BAAB et al.: Phase I clinical and pharmacokinetic trial of the farnesyltransferase inhibitor R115777 on a 21-day dosing schedule. Proc. Am. Soc. Clin. Oncol. (1999) 18:156a.
201. BRITTEN CD, ROWINSKY E, YAO S-L et al.: A Phase I and pharmacologic study of the farnesyl protein transfe-rase inhibitor L-778,123 in patients with solid cancers. Proc. Am. Soc. Clin. Oncol. (1999) 18:597.
202. RUBIN E, ABBRUZZESE J, MORRISON Bet al.: Phase I trial of the farnesyl transferase (FPTase) inhibitor L-778,123 on a 14 or 28-day dosing schedule. Proc. Am. Soc. Clin. Oncol. (2000) 19:689.
203. ADJEI AA, ERLICHMAN C, DAVIS JN et al.: A Phase I and pharmacologic study of the farnesyl protein transfe-rase inhibitor SCH66336 in patients with locally advanced or metastatic cancer. Proc. Am. Soc. Clin. Oncol. (1999) 18:598.
204. HURWITZ HI, COLVIN OM, PETROS WP et al.: A Phase I and pharmacokinetic study ofSCH 66336, a novel FPTI using a 2-week on, 2-week off schedule. Proc. Am. Soc. Clin. Oncol. (1999) 18:599.
205. ESKENS F, AWADA A, VERWEIJJ J et al.: Phase I and pharmacologic stud of continuous daily oral SCH66336, a novel farnesyl transferase inhibitor, in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. (1999) 18:156a.
206. SONNICHSEN D, DAMLE B, MANNING J et al.: Pharma-cokinetics and pharmacodynamics of the farnesyl-transferase inhibitor BMS-214662 in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. (2000) 19 (In Press).
207. RYAN DP, EDGE JP, SUPKO JG et al.: Phase I clinical trial of the farnesyl transferase inhibitor BMS-214662 in patients with advanced solid tumours. Proc. Am. Soc. Clin. Oncol. (2000) 19:720.
208. BASELGA J, NORTON L, ALBANELL J et al.: Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. (1998) 58:2825-2831. (Pubitemid 28311914)
209. GOLDENBERG MM: Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin. Ther. (1999) 21:309-318. (Pubitemid 29157789)
210. MOASSER MM, SEPP-LORENZINO L, KOHL NE et al.: Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc. Natl. Acad. Sci. USA (1998) 95:1369-1374. (Pubitemid 28103398)
211. SKRZAT SG, BOWDEN CR, END DW: Interaction of the farnesyl protein transferase inhibitor R115777 with cytotoxic chemotherapeutics in vitro and in vivo. Proc. Am. Assoc. Cancer Res. (1999) 40:523.
212. SHI B, GURNANI M, YAREMKO B et al.: Enhanced efficacy of the farnesyl protein transferase inhibitor SCH66336 in combination with paclitaxel. Proc. Am. Assoc. Cancer Res. (1999) 40:524.
213. SHARMA S, BRITTEN C, SPRIGGS D ET AL.: A Phase I and pharmacokinetic study of farnesyl transferase inhibitor L-778,123 administered as a seven day continuous infusion in combination with paclitaxel. Proc. Am. Soc. Clin. Oncol. (2000) 19 (In Press).
214. PEETERS M, VAN CUTSEM E, MARSE H et al.: Phase-I combination trial of the farnesyltransferase inhibitor (FTI) R115777 with A 5FU/LV regimen in advanced colorectal or pancreatic cancer. Proc. Am. Soc. Clin. Oncol. (1999) 18:859.
215. PATNAIK A, ECKHARDT SG, IZBICKA E et al.: A Phase I and pharmacologic (PK) study of the farnesyltransfe-rase inhibitor, R115777 in combination with gemcita-bine. Proc. Am. Soc. Clin. Oncol. (2000) 19:5A.
216. GRUGEL S, FINKENZELLER G, WEINDEL K et al.: Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J. Biol. Chem. (1995) 270:25915-25919.
217. RAK J, MITSUHASHI Y, BAYKO L et al.: Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibitionoftumor angiogene-sis. Cancer Res. (1995) 55:4575-4580.
218. BERNHARD EJ, KAO G, COX AD et al.: The farnesyl transferase inhibitor FTI-277 radiosensitizes H-Ras transformed rat embryo fibroblasts. Cancer Res. (1996) 56:1727-1730.
219. MCKENNA WG, WEISS MC, ENDLICH B et al.: Synergistic effects of the v-myc oncogene with H-Ras on radiore-sistance. Cancer Res. (1990) 50:97-102. (Pubitemid 20030001)
220. LANCET J, ROSENBLOTT J, LIEVELD JL et al.: Use of farnesyl transferase inhibitor R115777inrelapsedand refractory leukemia. Preliminary results of a phase I trial. Proc. Am. Soc. Clin. Oncol. (2000) 19:58.
221. EISENHAUER EA: Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. Ann. Oncol. (1998) 9:1047-1052.